Daiichi acquires controlling stake in Ranbaxy

The Japanese buyer aims to increase its initial stake in IndiaÆs largest pharmaceutical company to 50.1% for a total outlay of up to $4.6 billion.

Japanese pharmaceutical major Daiichi Sankyo will acquire a controlling interest in IndiaÆs largest pharmaceutical company Ranbaxy Laboratories at a price that values the Indian company at $8.5 billion.

The founders and controlling shareholders of Ranbaxy, the Singh family, have agreed to sell their 34.8% interest to Daiichi Sankyo at a price of Rs737 $17.17 a share. The deal, which also involves the issue of new shares and warrants to Daiichi, will precipitate an open offer to other shareholders in Ranbaxy,...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: daiichi | ranbaxy | religare

Print Edition

FinanceAsia Print Edition